MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-12-2026
Country |
 Schweiz |
IPO year |
2016 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBALSPB |
Shares |
89.9 M |
Market Cap[1] |
$ 4.39 B |
EBITDA (LTM) |
$ -601 M |
P/E (LTM) |
-8.96 |
P/S (LTM) |
1527.73 |
EPS (LTM) |
-6.16 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market |  USA |
 |
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market |  China |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market |  Britain |
 |
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
- | -19.68 % | $ 18.4 M | Nasdaq Capital Market |  Canada |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Aptorum Group Limited
APM
|
$ 0.9 | -2.33 % | $ 6.62 M | Nasdaq Global Select Market | China |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market |  France |
 |
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B | Nasdaq Global Select Market | France |
 |
ACADIA Pharmaceuticals
ACAD
|
$ 21.96 | -0.68 % | $ 3.64 B | Nasdaq Global Select Market,SPB | USA |
 |
RedHill Biopharma Ltd.
RDHL
|
$ 1.02 | -0.49 % | $ 428 M | Nasdaq Global Market |  Israel |
 |
Allakos
ALLK
|
- | - | $ 28.6 M | Nasdaq Global Select Market,SPB | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Advaxis
ADXS
|
- | -9.65 % | $ 45.9 M | Nasdaq Capital Market | USA |
 |
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | USA |
 |
Ampio Pharmaceuticals
AMPE
|
- | -11.43 % | $ 502 K | NYSE American | USA |
 |
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | USA |
 |
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | USA |
 |
Aligos Therapeutics
ALGS
|
$ 6.4 | 4.4 % | $ 63.3 M | Nasdaq Global Select Market | USA |
 |
Applied Therapeutics
APLT
|
- | - | $ 8.42 M | Nasdaq Global Market,SPB | USA |
 |
Aptinyx
APTX
|
- | -39.0 % | $ 4.57 M | Nasdaq Global Select Market | USA |
 |
Aridis Pharmaceuticals
ARDS
|
- | 17.91 % | $ 11.1 M | Nasdaq Capital Market | USA |
 |
Avenue Therapeutics
ATXI
|
- | -52.27 % | $ 4.45 M | Nasdaq Global Select Market | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
$ 21.41 | 1.9 % | $ 1 B | Nasdaq Global Select Market | USA |
 |
Aravive
ARAV
|
- | -13.39 % | $ 1.45 M | Nasdaq Global Select Market | USA |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
AstraZeneca PLC
AZN
|
- | - | $ 96.9 B | Nasdaq Global Select Market | Britain |
 |
BioDelivery Sciences International
BDSI
|
- | -4.8 % | $ 255 M | Nasdaq Global Select Market | USA |
 |
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market | Canada |
 |
Brainstorm Cell Therapeutics
BCLI
|
- | -2.5 % | $ 5.88 M | Nasdaq Capital Market | USA |
 |
Kazia Therapeutics Limited
KZIA
|
$ 12.26 | 3.72 % | $ 1.62 B | Nasdaq Global Select Market |  Australia |
 |
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | USA |
 |
BioNTech SE
BNTX
|
$ 105.46 | -0.09 % | $ 27.2 B | Nasdaq Global Select Market | Germany |
 |
BeiGene, Ltd.
BGNE
|
- | 0.49 % | $ 251 B | Nasdaq Global Select Market |  Cayman-islands |
 |
Ayala Pharmaceuticals
AYLA
|
- | - | $ 7.46 M | Nasdaq Global Market | Israel |
 |
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | USA |
 |
Aquestive Therapeutics
AQST
|
$ 4.08 | 0.25 % | $ 436 M | Nasdaq Global Market | USA |
 |
Arcutis Biotherapeutics
ARQT
|
$ 23.26 | 1.75 % | $ 2.96 B | Nasdaq Global Select Market,SPB | USA |
 |
Cara Therapeutics
CARA
|
- | -3.03 % | $ 260 M | Nasdaq Global Market,SPB | USA |
 |
Autolus Therapeutics plc
AUTL
|
$ 1.44 | -5.88 % | $ 383 M | Nasdaq Global Select Market | Britain |
 |
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Nasdaq Capital Market | Canada |
 |
BioXcel Therapeutics
BTAI
|
$ 1.06 | -3.64 % | $ 12.9 M | Nasdaq Global Select Market,SPB | USA |
 |
CASI Pharmaceuticals
CASI
|
- | - | $ 35.4 M | Nasdaq Capital Market | USA |
 |
AVROBIO
AVRO
|
- | 1083.1 % | $ 745 M | Nasdaq Global Select Market | USA |
 |
Cabaletta Bio
CABA
|
$ 2.95 | -3.28 % | $ 296 M | Nasdaq Global Select Market | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 2.91 | -1.36 % | $ 4.79 M | NYSE American | Israel |
 |
bluebird bio
BLUE
|
- | - | $ 546 M | Nasdaq Global Select Market,SPB | USA |
 |
CymaBay Therapeutics
CBAY
|
- | - | $ 3.45 B | Nasdaq Global Select Market | USA |
 |
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.